Cyclic intravenous pamidronate treatment in children with nodulosis, arthropathy and osteolysis syndrome

• Published in: Annals of the rheumatic diseases Vol. 65; no. 12; pp. 1672 - 1673
• Main Authors: Al-Mayouf, S M, Madi, S M, Bin-Abbas, B S
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.12.2006; BMJ; BMJ Publishing Group LTD; BMJ Group
• Subjects: Adolescent; Biological and medical sciences; Bone density; Bone Density - drug effects; Bone Density Conservation Agents - therapeutic use; Bones, joints and connective tissue. Antiinflammatory agents; Child; Child, Preschool; Diphosphonates - therapeutic use; Diseases of the osteoarticular system; Hajdu-Cheney Syndrome - drug therapy; Humans; Infusions, Intravenous; Letters; Medical sciences; Miscellaneous. Osteoarticular involvement in other diseases; Osteoporosis; Pharmacology. Drug treatments; Phosphatase; Prospective Studies; Treatment Outcome; Human; Treatment; Intravenous administration; Diseases of the osteoarticular system; Arthropathy; Diphosphonic acid derivatives; Osteolysis; Bisphosphonates; Child; Pamidronic acid
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/ard.2005.035725

The patients had clinical and functional assessments using the Childhood Health Assessment Questionaire and the Visual Analogue Scale. 5 All patients had normal serum levels of calcium, magnesium, phosphorus, alkaline phosphatase, parathyroid hormone, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, serum osteocalcin, urine spot for cross-linked N-telopeptide type I collagen (NTX), calcium, phosphorus and creatinine. x Rays of hands and feet, and bone mineral density (BMD) of the lumbar spine and the whole body, were assessed before and at the end of the treatment course. z Scores and the number of standard deviations (SD) for BMD above or below the mean for age-matched controls were derived on the basis of the manufacturer's data.